EG24223A - Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiopehene and salts thereof - Google Patents
Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiopehene and salts thereofInfo
- Publication number
- EG24223A EG24223A EG20010461A EG20010461A EG24223A EG 24223 A EG24223 A EG 24223A EG 20010461 A EG20010461 A EG 20010461A EG 20010461 A EG20010461 A EG 20010461A EG 24223 A EG24223 A EG 24223A
- Authority
- EG
- Egypt
- Prior art keywords
- piperidin
- benzo
- methoxyphenyl
- phenoxy
- ethoxy
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 125000005605 benzo group Chemical group 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 229960004308 acetylcysteine Drugs 0.000 abstract 1
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20323500P | 2000-05-08 | 2000-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EG24223A true EG24223A (en) | 2008-11-10 |
Family
ID=22753086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EG20010461A EG24223A (en) | 2000-05-08 | 2001-05-05 | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiopehene and salts thereof |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1357903B1 (de) |
| JP (1) | JP2003535827A (de) |
| KR (1) | KR100806992B1 (de) |
| CN (1) | CN1283250C (de) |
| AR (1) | AR028401A1 (de) |
| AT (1) | ATE348605T1 (de) |
| AU (2) | AU5531001A (de) |
| BR (1) | BR0110620A (de) |
| CA (2) | CA2408563A1 (de) |
| CZ (1) | CZ20023651A3 (de) |
| DE (1) | DE60125416T2 (de) |
| DZ (1) | DZ3376A1 (de) |
| EA (1) | EA004871B1 (de) |
| EC (1) | ECSP014066A (de) |
| EG (1) | EG24223A (de) |
| ES (1) | ES2276784T3 (de) |
| HR (1) | HRP20020883A2 (de) |
| HU (1) | HUP0302190A3 (de) |
| IL (2) | IL152699A0 (de) |
| MX (1) | MXPA02010923A (de) |
| NO (1) | NO20025219D0 (de) |
| NZ (1) | NZ521393A (de) |
| PE (1) | PE20011255A1 (de) |
| PL (1) | PL365472A1 (de) |
| SK (1) | SK286346B6 (de) |
| SV (1) | SV2002000435A (de) |
| TW (1) | TWI225787B (de) |
| UA (1) | UA77941C2 (de) |
| WO (1) | WO2001085147A2 (de) |
| ZA (1) | ZA200207651B (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6653479B1 (en) | 1999-07-29 | 2003-11-25 | Eli Lilly And Company | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride |
| US6610706B1 (en) | 1999-07-29 | 2003-08-26 | Eli Lilly And Company | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| JP4593469B2 (ja) * | 2003-09-22 | 2010-12-08 | 杏林製薬株式会社 | 変色改善された５−アミノサリチル酸固形製剤およびその保存方法 |
| WO2016024369A1 (ja) * | 2014-08-13 | 2016-02-18 | テバ製薬株式会社 | がん治療用医薬組成物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR003930A1 (es) * | 1995-02-28 | 1998-09-30 | Lilly Co Eli | Procedimiento para preparar compuestos de 2-fenil-3-fenoxi o feniltio-benzotiofeno y sales farmaceuticamente aceptables, compuestos intermediarios de aplicación exclusiva en dicho procedimiento y metodo para preparar los compuestos intermediarios mencionados |
| ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
| AU6335600A (en) * | 1999-07-29 | 2001-02-19 | Eli Lilly And Company | A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride |
| ES2208384T3 (es) * | 1999-07-29 | 2004-06-16 | Eli Lilly And Company | Forma cristalina de clorhidrato de 6 hidroxi-3-(4-(2-(piperidin-1-il)-etoxi)-fenoxi)2--(4-metoxifenil)-benzo(b)tiofeno. |
| ZA200003837B (en) * | 1999-07-29 | 2002-01-28 | Lilly Co Eli | A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride. |
-
2001
- 2001-04-30 NZ NZ521393A patent/NZ521393A/en unknown
- 2001-04-30 SK SK1565-2002A patent/SK286346B6/sk not_active IP Right Cessation
- 2001-04-30 HU HU0302190A patent/HUP0302190A3/hu unknown
- 2001-04-30 DZ DZ013376A patent/DZ3376A1/xx active
- 2001-04-30 CA CA002408563A patent/CA2408563A1/en not_active Abandoned
- 2001-04-30 UA UA2002118788A patent/UA77941C2/uk unknown
- 2001-04-30 CN CNB018091296A patent/CN1283250C/zh not_active Expired - Fee Related
- 2001-04-30 AT AT01928454T patent/ATE348605T1/de not_active IP Right Cessation
- 2001-04-30 DE DE60125416T patent/DE60125416T2/de not_active Expired - Fee Related
- 2001-04-30 CZ CZ20023651A patent/CZ20023651A3/cs unknown
- 2001-04-30 EA EA200201186A patent/EA004871B1/ru not_active IP Right Cessation
- 2001-04-30 AU AU5531001A patent/AU5531001A/xx active Pending
- 2001-04-30 BR BR0110620-1A patent/BR0110620A/pt not_active Application Discontinuation
- 2001-04-30 PL PL01365472A patent/PL365472A1/xx not_active Application Discontinuation
- 2001-04-30 JP JP2001581801A patent/JP2003535827A/ja active Pending
- 2001-04-30 EP EP01928454A patent/EP1357903B1/de not_active Expired - Lifetime
- 2001-04-30 HR HR20020883A patent/HRP20020883A2/hr not_active Application Discontinuation
- 2001-04-30 IL IL15269901A patent/IL152699A0/xx unknown
- 2001-04-30 ES ES01928454T patent/ES2276784T3/es not_active Expired - Lifetime
- 2001-04-30 AU AU2001255310A patent/AU2001255310C1/en not_active Ceased
- 2001-04-30 WO PCT/US2001/011736 patent/WO2001085147A2/en not_active Ceased
- 2001-04-30 CA CA002691739A patent/CA2691739A1/en not_active Abandoned
- 2001-04-30 MX MXPA02010923A patent/MXPA02010923A/es active IP Right Grant
- 2001-04-30 KR KR1020027014923A patent/KR100806992B1/ko not_active Expired - Fee Related
- 2001-05-02 AR ARP010102074A patent/AR028401A1/es unknown
- 2001-05-02 TW TW090110500A patent/TWI225787B/zh not_active IP Right Cessation
- 2001-05-04 PE PE2001000402A patent/PE20011255A1/es not_active Application Discontinuation
- 2001-05-05 EG EG20010461A patent/EG24223A/xx active
- 2001-05-07 SV SV2001000435A patent/SV2002000435A/es not_active Application Discontinuation
- 2001-05-08 EC EC2001004066A patent/ECSP014066A/es unknown
-
2002
- 2002-09-23 ZA ZA200207651A patent/ZA200207651B/en unknown
- 2002-10-31 NO NO20025219A patent/NO20025219D0/no not_active Application Discontinuation
- 2002-11-07 IL IL152699A patent/IL152699A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO950297D0 (no) | Prolinamidderivater | |
| EP1246622A4 (de) | Neue substituierte dosisformen von benzimidazolen und verfahren zur deren verwendung | |
| MA26926A1 (fr) | Procede d'obtention de formulations aqueuses de principes actifs sensibles a l'oxydation. | |
| UY27320A1 (es) | Nuevas composiciones farmacéuticas | |
| DK0759919T3 (da) | Azolidindioner som antihyperglykæmiske midler | |
| AR028706A1 (es) | Tiazina oxazolidinona | |
| JO2239B1 (en) | Method for preparing benzothophen derivatives | |
| MY135954A (en) | Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid | |
| PL365472A1 (en) | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof | |
| NO933010D0 (no) | 4-((2-benzotiazolyl)metylamino)alfa-((3,4-difluorfenoksy)metyl)-1-piperidinetanol | |
| BR9812982A (pt) | Agente anti-reumático | |
| MY141869A (en) | Mouth rinse compositions | |
| ATE358128T1 (de) | Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation | |
| DK0913151T3 (da) | Anti-helicobacter Pylori-præparater indeholdende 1-methylcarbapenemderivater som den aktive bestanddel | |
| EP1757291A3 (de) | Stabilisierte Formulierungen von 6-Hydroxy-3-(4-[2-(Piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen und deren Salze | |
| DK1174131T3 (da) | Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom | |
| NZ505994A (en) | Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases | |
| ATE214917T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend dopamin oder dobutamin | |
| DK0673913T3 (da) | Calcium-alkalimetalcitratforbindelser samt deres anvendelse som lægemidler | |
| WO2002022567A8 (en) | Novel thio derivatives of sordarin as antifungal agents | |
| NO20010244L (no) | Medikamenter inneholdende polyhydroksyalkylpyrazinderivater, deres fremstilling samt medikamenter inneholdende derivatene |